Definium Therapeutics earnings were -$237.5M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest DFTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$77.1M, up 52.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, DFTX reported annual earnings of -$183.8M, with 69.1% growth. The next DFTX earnings date is Jul 30, 2026.
Definium Therapeutics Earnings Reports & History FAQ
What were Definium Therapeutics's earnings last quarter?
On DFTX's earnings call on May 7, 2026, Definium Therapeutics (NASDAQ: DFTX) reported Q1 2026 earnings per share (EPS) of -$0.71, up 162.96% year over year. Total DFTX earnings for the quarter were -$77.10 million. In the same quarter last year, Definium Therapeutics's earnings per share (EPS) was -$0.27.
The next DFTX earnings date is Jul 30, 2026. Add DFTX to your watchlist to be reminded of Definium Therapeutics's next earnings date.
Is Definium Therapeutics profitable or losing money?
As of the last Definium Therapeutics earnings report, Definium Therapeutics is currently losing money. Definium Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$237.54 million, a 206.01% increase year over year.
What was DFTX's earnings growth in the past year?
As of Definium Therapeutics's earnings date in May 7, 2026, Definium Therapeutics's earnings has grown year over year. DFTX earnings in the past year totalled -$237.54 million.
What are Definium Therapeutics's earnings expectations?
The current EPS estimate for Definium Therapeutics's earnings report in Jul 30, 2026 is -$0.55.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.